For these reasons, recent expert panel recommendations emphasize comprehensive, lifelong screening across numerous cancer types, beginning as soon as an individual has been confirmed to carry a TP53 PV or meets the “classic clinical definition” of LFS with no TP53 PV. This evidence concerns the gene TP53 and cancer.